COO vs. XBI

Last updated Jun 5, 2026

COO (The Cooper Companies, Inc.) is a stock, while XBI (SPDR S&P Biotech ETF) is Health & Biotech Equities fund tracking the S&P Biotechnology Select Industry Index. Over the past 10 years, COO returned 4.30%/yr vs 8.53%/yr for XBI. At a 0.43 correlation, their price movements are largely independent.

Performance

COO vs. XBI - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in The Cooper Companies, Inc. (COO) and SPDR S&P Biotech ETF (XBI). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, COO achieves a -24.33% return, which is significantly lower than XBI's 9.42% return. Over the past 10 years, COO has underperformed XBI with an annualized return of 4.30%, while XBI has yielded a comparatively higher 8.53% annualized return.

COO

• 1D: 2.78%
• 1M: 1.26%
• YTD: -24.33%
• 6M: -19.49%
• 1Y: -8.01%
• 3Y*: -11.14%
• 5Y*: -8.26%
• 10Y*: 4.30%

XBI

• 1D: 2.77%
• 1M: -0.28%
• YTD: 9.42%
• 6M: 8.61%
• 1Y: 62.35%
• 3Y*: 15.65%
• 5Y*: 1.14%
• 10Y*: 8.53%

*Multi-year figures are annualized to reflect compound growth (CAGR)

COO vs. XBI - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
COO The Cooper Companies, Inc.	-24.33%	-10.85%	-2.83%	14.47%	-21.06%	15.33%	13.10%	26.27%	16.84%	24.59%
XBI SPDR S&P Biotech ETF	9.42%	35.89%	1.01%	7.60%	-25.87%	-20.45%	48.33%	32.56%	-15.28%	43.77%

Correlation

The correlation between COO and XBI is 0.36, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.36
Correlation (3Y) Calculated over the trailing 3-year period	0.40
Correlation (5Y) Calculated over the trailing 5-year period	0.43
Correlation (10Y) Calculated over the trailing 10-year period	0.42
Correlation (All Time) Calculated using the full available price history since Feb 7, 2006	0.43

Return for Risk

COO vs. XBI — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

COO

COO Risk / Return Rank: 29
COO Sharpe Ratio Rank: 30
COO Sortino Ratio Rank: 26
COO Omega Ratio Rank: 27
COO Calmar Ratio Rank: 33
COO Martin Ratio Rank: 30

XBI

XBI Risk / Return Rank: 80
XBI Sharpe Ratio Rank: 77
XBI Sortino Ratio Rank: 75
XBI Omega Ratio Rank: 67
XBI Calmar Ratio Rank: 93
XBI Martin Ratio Rank: 89

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

COO vs. XBI - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for The Cooper Companies, Inc. (COO) and SPDR S&P Biotech ETF (XBI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	COO	XBI	Difference
Sharpe ratio: Return per unit of total volatility	-0.27	2.45	-2.72
Sortino ratio: Return per unit of downside risk	-0.18	3.32	-3.51
Omega ratio: Gain probability vs. loss probability	0.98	1.40	-0.42
Calmar ratio: Return relative to maximum drawdown	-0.27	6.45	-6.71
Martin ratio: Return relative to average drawdown	-0.65	19.53	-20.19
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

COO vs. XBI - Sharpe Ratio Comparison

The current COO Sharpe Ratio is -0.27, which is lower than the XBI Sharpe Ratio of 2.45. The chart below compares the historical Sharpe Ratios of COO and XBI, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	COO	XBI	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.27	2.45	-2.72
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.29	0.04	-0.32
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.16	0.27	-0.11
Sharpe Ratio (All Time) Calculated using the full available price history	0.11	0.36	-0.25

Drawdowns

COO vs. XBI - Drawdown Comparison

The maximum COO drawdown since its inception was -98.88%, which is greater than XBI's maximum drawdown of -63.89%. Use the drawdown chart below to compare losses from any high point for COO and XBI.

Drawdown Indicators

	COO	XBI	Difference
Max Drawdown Largest peak-to-trough decline	-98.88%	-63.89%	-34.99%
Max Drawdown (1Y) Largest decline over 1 year	-30.05%	-9.72%	-20.33%
Max Drawdown (3Y) Largest decline over 3 years	-46.97%	-32.99%	-13.98%
Max Drawdown (5Y) Largest decline over 5 years	-48.24%	-54.71%	+6.47%
Max Drawdown (10Y) Largest decline over 10 years	-48.24%	-63.89%	+15.65%
Current Drawdown Current decline from peak	-45.57%	-22.89%	-22.68%
Average Drawdown Average peak-to-trough decline	-40.56%	-20.93%	-19.63%
Ulcer Index Depth and duration of drawdowns from previous peaks	12.30%	3.20%	+9.10%

Volatility

COO vs. XBI - Volatility Comparison

The current volatility for The Cooper Companies, Inc. (COO) is 6.59%, while SPDR S&P Biotech ETF (XBI) has a volatility of 9.69%. This indicates that COO experiences smaller price fluctuations and is considered to be less risky than XBI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	COO	XBI	Difference
Volatility (1M) Calculated over the trailing 1-month period	6.59%	9.69%	-3.10%
Volatility (6M) Calculated over the trailing 6-month period	17.55%	20.31%	-2.76%
Volatility (1Y) Calculated over the trailing 1-year period	29.56%	25.60%	+3.96%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	28.86%	32.20%	-3.34%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	27.70%	32.00%	-4.30%

Dividends

COO vs. XBI - Dividend Comparison

COO has not paid dividends to shareholders, while XBI's dividend yield for the trailing twelve months is around 0.33%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
COO The Cooper Companies, Inc.	0.00%	0.00%	0.00%	0.02%	0.02%	0.01%	0.02%	0.02%	0.02%	0.03%	0.03%	0.04%
XBI SPDR S&P Biotech ETF	0.33%	0.37%	0.15%	0.02%	0.00%	0.04%	0.20%	0.00%	0.28%	0.24%	0.26%	0.61%

Frequently Asked Questions

Can I hold both COO and XBI in my portfolio?

COO and XBI have a correlation of 0.36, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, COO or XBI?

XBI has higher volatility (9.69%) compared to COO (6.59%). In terms of maximum drawdown, COO dropped -98.88% vs XBI's -63.89%.

Which has better risk-adjusted returns?

XBI currently has the higher Sharpe Ratio (2.45 vs -0.27), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.